Status:
RECRUITING
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Neuroendocrine Tumors
Neuroendocrine Neoplasm
Eligibility:
All Genders
18-80 years
Brief Summary
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatmen...
Detailed Description
Neuroendocrine Neoplasm (NEN) are heterogeneous disease in terms of origin, localization and clinical presentation. Annual incidence of NEN is increasing in the last 30 years, even if the reasons unde...
Eligibility Criteria
Inclusion
- Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);
- Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).
Exclusion
- Severe chronic kidney disease (stage 4-5);
- Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;
- Other non-neuroendocrine malignancies.
Key Trial Info
Start Date :
September 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04464122
Start Date
September 14 2020
End Date
December 31 2025
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Andrea M Isidori
Rome, Italy, Italy, 00161